Free Trial

Qualigen Therapeutics Q2 2023 Earnings Report

Qualigen Therapeutics logo
$3.90 -0.14 (-3.47%)
(As of 12/20/2024 05:16 PM ET)

Qualigen Therapeutics EPS Results

Actual EPS
-$34.50
Consensus EPS
-$26.00
Beat/Miss
Missed by -$8.50
One Year Ago EPS
N/A

Qualigen Therapeutics Revenue Results

Actual Revenue
$1.63 million
Expected Revenue
$1.60 million
Beat/Miss
Beat by +$30.00 thousand
YoY Revenue Growth
N/A

Qualigen Therapeutics Announcement Details

Quarter
Q2 2023
Time
Before Market Opens

Conference Call Resources

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Qualigen Therapeutics Earnings Headlines

Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 7.8% - Here's Why
Rare "crisis signal" triggers for third time in U.S. market
A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.
Qualigen announces $4.5M private placement of Preferred Shares
See More Qualigen Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Qualigen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qualigen Therapeutics and other key companies, straight to your email.

About Qualigen Therapeutics

Qualigen Therapeutics (NASDAQ:QLGN), a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

View Qualigen Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings